Mohammed Ahmed Akkaif | Cardiovascular Pharmacology | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Dr. Mohammed Ahmed Akkaif | Cardiovascular Pharmacology | Best Researcher Award

Dr. Mohammed Ahmed Akkaif, Fudan University, China

Dr. Mohammed Ahmed Akkaif is a Postdoctoral Researcher in the Department of Cardiology at Fudan University, China. He earned his Ph.D. in Clinical Pharmacy from Universiti Sains Malaysia in 2023, specializing in precision medicine, pharmacogenetics, and cardiology. A Young Ambassador for the European Association of Preventive Cardiology (2022–2024), he has published 34 peer-reviewed articles, with 29 indexed in SCI, and has over 2,179 citations. Recognized with the Young Researchers Award (ESC Asia 2022), he is a reviewer for 50+ high-impact journals. His research focuses on optimizing antithrombotic drug therapies through pharmacometabolomics for personalized cardiovascular treatment.

AUTHOR PROFILE

Scopus Profile

Orcid Profile

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Dr. Mohammed Ahmed Akkaif began his academic journey with a strong foundation in Clinical Pharmacy at Universiti Sains Malaysia, where he completed his Doctor of Philosophy (PhD) in July 2023. During his PhD, he focused on the intersection of clinical pharmacy and biotechnology, gaining expertise in personalized and precision medicine. His academic accomplishments included publishing 10 articles (8 in SCI Q1 and Q2 journals) and presenting at six international conferences. This period also saw him design innovative approaches to enhance antithrombotic drug treatment, particularly through CYP2C19 genotype-guided antiplatelet therapy.

💼PROFESSIONAL ENDEAVORS:

Currently, Dr. Akkaif serves as a Postdoctoral Researcher in the Department of Cardiology at Fudan University’s Qingpu Branch of Zhongshan Hospital, China. His role involves leading advanced research in cardiovascular medicine, with a specialized focus on the clinical application of personalized medicine in cardiology. Additionally, he has served as a Young Ambassador for the European Association of Preventive Cardiology (EAPC) from 2022 to 2024, demonstrating his commitment to advancing heart health on a global scale. He has also contributed his expertise to several prestigious journals, with over 50 reviews in high-impact journals such as Journal of the American Heart Association and Arteriosclerosis, Thrombosis, and Vascular Biology.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR PHARMACOLOGY:

Dr. Akkaif’s research is primarily focused on pharmacogenetics and pharmacometabolomics, with a goal of improving personalized treatment strategies in cardiology. His work delves into the optimization of antithrombotic drug therapies through genetic and metabolic profiling, which holds the potential to revolutionize treatment protocols, making them more tailored to individual patient profiles. His research also bridges the gap between clinical pharmacy and biotechnology, aiming to develop more effective, individualized approaches to cardiovascular health.

🌍IMPACT AND INFLUENCE:

Dr. Akkaif’s contributions have already made a significant impact on both academic research and the practical application of precision medicine. He has been honored with the Young Researchers Award at the 2022 ESC Asia Conference in Singapore, highlighting his early recognition in the field. His research has also led to the publication of 34 peer-reviewed articles, with 29 of them indexed in SCI (Clarivate), reflecting his growing influence in the field of cardiovascular pharmacology. His work has contributed to advancing the understanding of genetic factors in drug response, and his findings are regularly cited by researchers and clinicians alike.

📚ACADEMIC CITATIONS AND RECOGNITION:

Dr. Akkaif’s publications have earned him considerable academic recognition, with a cumulative citation count of 2,179 as of now. This citation count reflects the profound influence his work has had on the scientific community, particularly in the areas of pharmacogenetics, pharmacometabolomics, and cardiology. His ability to produce impactful, high-quality research is evident through his consistent presence in top-tier journals, where his findings continue to shape the discourse on personalized medicine.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

As Dr. Akkaif continues his postdoctoral work at Fudan University, his future contributions are poised to expand on his research in precision medicine and cardiology. Given his accomplishments thus far, his research promises to lead to more personalized treatment options for cardiovascular diseases, potentially transforming clinical practices and improving patient outcomes globally. His ongoing efforts in understanding the genetic and metabolic factors influencing drug efficacy will likely place him at the forefront of the personalized medicine movement, paving the way for future innovations in the medical field.

🏆KEY AWARDS AND HONORS:

  • Young Researchers Award at the 2022 ESC Asia Conference (Singapore)

  • Second Prize for the Young Investigator Award at the ESC Asia Congress in Singapore 2022

  • Young Ambassador of the European Association of Preventive Cardiology (EAPC) (2022–2024)

  • Reviewing Excellence for over 50 high-impact SCI Q1 and Q2 journals

🌍CONCLUSION:

Dr. Mohammed Ahmed Akkaif’s groundbreaking research in precision medicine and cardiology continues to shape the future of personalized healthcare. With a strong academic background, numerous publications, and recognition through prestigious awards, his work is making significant contributions to improving cardiovascular treatments. His role as a Young Ambassador for the European Association of Preventive Cardiology further highlights his dedication to global health. As he advances his postdoctoral research at Fudan University, Dr. Akkaif’s future endeavors hold the potential to revolutionize clinical practices, particularly in pharmacogenetics and pharmacometabolomics, ensuring more effective and individualized patient care.

TOP NOTABLE PUBLICATIONS:

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in …

Authors: AJ Ferrari, DF Santomauro, A Aali, YH Abate, C Abbafati, H Abbastabar, …

Journal: The Lancet

Year: 2024

Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease …

Authors: M Brauer, GA Roth, AY Aravkin, P Zheng, KH Abate, YH Abate, C Abbafati, …

Journal: The Lancet

Year: 2024

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the …

Authors: The Lancet

Year: 2024

Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050

Authors: M Naghavi, SE Vollset, KS Ikuta, LR Swetschinski, AP Gray, EE Wool, …

Journal: The Lancet

Year: 2024

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Authors: SE Vollset, HS Ababneh, YH Abate, C Abbafati, R Abbasgholizadeh, …

Journal: The Lancet

Year: 2024

Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Authors: VL Feigin, MD Abate, YH Abate, S Abd ElHafeez, F Abd-Allah, …

Journal: The Lancet Neurology

Year: 2024

Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Authors: NV Bhattacharjee, AE Schumacher, A Aali, YH Abate, R Abbasgholizadeh, …

Journal: The Lancet

Year: 2024

The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD)

Authors: MA Akkaif, NAA Daud, A Sha’aban, ML Ng, MAS Abdul Kader, DA Noor

Journal: Molecules

Year: 2021

A review of the effects of ticagrelor on adenosine concentration and its clinical significance

Authors: MA Akkaif, ML Ng, MASA Kader, NAA Daud, A Sha’aban, B Ibrahim

Journal: Pharmacological Reports

Year: 2021

National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990–2021, and forecasts up to 2050

Authors: M Ng, X Dai, RM Cogen, M Abdelmasseh, A Abdollahi, A Abdullahi, …

Journal: The Lancet

Year: 2024

 

Wang Yanqiang | Atherosclerosis | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Prof. Wang Yanqiang | Atherosclerosis | Best Researcher Award

Prof. Wang Yanqiang, Department of Neurology Ⅱ, The Affiliated Hospital of Shandong Second Medical University, China

Prof. Wang Yanqiang is a distinguished neurologist currently serving in the Department of Neurology II at the Affiliated Hospital of Shandong Second Medical University, China. With a strong academic background, Prof. Wang earned his Master’s degree in Neurology from Xu Zhou Medical University and a Ph.D. from Sun Yat-sen University. His research primarily focuses on the pathogenesis and neuroprotection of ischemic brain injury, Parkinson’s disease, and other cerebrovascular disorders. Over the years, Prof. Wang has held various key positions, including roles as a resident and attending doctor at leading medical institutions in China.

AUTHOR PROFILE

Orcid Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Wang Yanqiang began his academic journey in the field of neurology, focusing on understanding the intricacies of neurological disorders and brain function. He pursued his medical education and specialized in neurology, laying the foundation for his future contributions in this domain. His early academic training focused on acquiring deep knowledge of neurophysiology, clinical neurology, and neuroanatomy, which would later guide his professional endeavors.

🏥PROFESSIONAL ENDEAVORS:

Prof. Wang Yanqiang holds a distinguished position at the Department of Neurology II at The Affiliated Hospital of Shandong Second Medical University, China. Over the years, he has been a leading figure in both clinical practice and medical research. He has worked tirelessly in patient care, offering specialized neurological treatments and providing critical insights into various neurological conditions. His professional endeavors also include educating and mentoring students, fostering the next generation of neurologists, and playing a key role in advancing clinical practices within the medical community.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON Atherosclerosis

Prof. Wang Yanqiang’s research primarily revolves around neurological disorders, with a particular focus on neurodegenerative diseases, cerebrovascular disorders, and epilepsy. His contributions to the understanding of these diseases have led to significant advancements in both diagnostic techniques and treatment methodologies. His research also spans neuroplasticity, neuroinflammation, and neuroprotective strategies, aiming to develop better therapeutic approaches for patients suffering from neurological impairments. Additionally, Prof. Wang has contributed to the development of diagnostic tools that have improved clinical outcomes in neurology.

🌍IMPACT AND INFLUENCE:

Prof. Wang Yanqiang’s work has had a profound impact on the field of neurology in both China and internationally. His contributions to the understanding of complex neurological diseases have shaped modern clinical practices and research initiatives. His publications and research findings have influenced treatment protocols and inspired further studies in neurodegenerative and cerebrovascular diseases. As a prominent figure in neurology, Prof. Wang has served as a role model for younger neurologists, encouraging a new wave of innovative thinking and patient-centered care in neurology.

📚ACADEMIC CITATIONS AND RECOGNITION:

Prof. Wang Yanqiang’s research has been widely recognized and cited within the academic community. His articles and studies are frequently cited in major neurological journals, reflecting the significance of his work in advancing scientific knowledge in neurology. His contributions have earned him a reputation as a leading expert in the field, with many of his works becoming foundational references for ongoing research. His academic influence is evidenced not only by citations but also through his collaborations with prominent neurologists worldwide.

🌟LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Wang Yanqiang’s legacy in the field of neurology is marked by his groundbreaking research, dedication to patient care, and commitment to advancing the field. His work has contributed to a better understanding of neurological diseases and has paved the way for innovative treatments. As the field of neurology continues to evolve, Prof. Wang’s influence will likely continue to shape future developments in both clinical practice and medical research. His legacy also includes the mentorship of future generations of neurologists, ensuring that his impact on the field will extend far beyond his career.

🚀CONCLUSION:

Prof. Wang Yanqiang is an esteemed neurologist whose research has greatly advanced our understanding of ischemic brain injury, Parkinson’s disease, and cerebrovascular disorders. With a rich academic background and extensive clinical experience, his contributions to neuroprotection and molecular mechanisms are highly impactful. Through his numerous publications, Prof. Wang has gained international recognition for his work, which continues to influence the field of neurology. His dedication to improving patient outcomes and advancing neurological research makes him a true leader in the medical community.

TOP NOTABLE PUBLICATIONS

  • Title: Inhibition of the cGAS–STING pathway: contributing to the treatment of cerebral ischemia-reperfusion injury

    • Journal: Neural Regeneration Research
    • Volume: 2025-07
    • Year: 2025

  • Title: Exploring the Neuroprotective Effects of Lithium in Ischemic Stroke: A literature review

    • Journal: International Journal of Medical Sciences
    • Volume: 2024
    • Year: 2024

  • Title: Risk Factors and Clinical Characteristics of First-ever Ischemic Stroke Caused by ICAS with Leukoaraiosis

    • Journal: International Journal of Medical Sciences
    • Volume: 2024
    • Year: 2024

  • Title: 1,25-D3 ameliorates ischemic brain injury by alleviating endoplasmic reticulum stress and ferroptosis: Involvement of vitamin D receptor and p53 signaling

    • Journal: Cellular Signalling
    • Volume: 2024-10
    • Year: 2024

  • Title: A case of acute basilar artery occlusion due to atherosclerotic disease revascularized by drug-coated balloon dilation

    • Journal: International Journal of Neuroscience
    • Volume: 2024-09
    • Year: 2024

  • Title: A case report of drug-coated balloon dilation angioplasty in a patient with acute atherosclerotic basilar artery occlusion

    • Journal: Asian Journal of Surgery
    • Volume: 2024-09
    • Year: 2024

  • Title: Global, regional, and national epidemiology of ischemic stroke from 1990 to 2021

    • Journal: European Journal of Neurology
    • Volume: 2024-09-17
    • Year: 2024

  • Title: Genetic insights into the relationship between immune cell characteristics and ischemic stroke: A bidirectional Mendelian randomization study

    • Journal: European Journal of Neurology
    • Volume: 2024-05
    • Year: 2024

  • Title: Assessing tobacco-related ischemic stroke in Pakistan (1990-2019): Insights from the Global Burden of Disease Study

    • Journal: Tobacco Induced Diseases
    • Volume: 2024-03-28
    • Year: 2024

  • Title: First report of a p.Cys484Tyr Notch3 mutation in a CADASIL patient with acute bilateral multiple subcortical infarcts—case report and brief review

    • Journal: BMC Neurology
    • Year: 2024

Zhuofeng Lin | Myocardial infarction | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Prof. Dr. Zhuofeng Lin | Myocardial infarction | Best Researcher Award 

Prof. Dr. Zhuofeng Lin, Guangdong Medical University, China

Prof. Dr. Zhuofeng Lin is the Dean of the Experimental Animal Center and Dean of the Innovational Center of Cardiometabolic Disease at Guangdong Medical University, China. His research focuses on cross-organ communication in cardiovascular and metabolic diseases, particularly the role of metabolic hormones and obesity. He has made significant contributions to understanding FGF21 metabolic regulation, impacting blood glucose stability, blood pressure control, and anti-atherosclerosis therapies. His work also explores new targets for anti-myocardial infarction, heart failure, and vascular calcification drugs, driving innovation in metabolic and cardiovascular medicine. His research is widely recognized in international medical science.

AUTHOR PROFILE

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Dr. Zhuofeng Lin’s academic journey began with a strong foundation in medical sciences, focusing on cardiovascular and metabolic diseases. His early research explored physiological mechanisms and metabolic interactions, leading him to specialize in cross-organ communication and metabolic regulation. His education and initial training laid the groundwork for his extensive contributions to cardiometabolic research.

🏢PROFESSIONAL ENDEAVORS:

Prof. Lin has held prestigious positions at Guangdong Medical University, where he currently serves as:

  • Dean of the Experimental Animal Center 🐁
  • Dean of the Innovational Center of Cardiometabolic Disease 🫀

His leadership in these institutions has driven significant advancements in experimental research methodologies and the development of innovative treatment strategies for metabolic disorders.

🔍CONTRIBUTIONS AND RESEARCH FOCUS ON MYOCARDIAL INFARCTION:

Prof. Lin’s research is dedicated to practical applications, with a strong emphasis on:

  • Cross-organ communication in cardiovascular and metabolic diseases
  • Pathogenesis of cardiometabolic disorders linked to metabolic hormones and obesity
  • Fibroblast Growth Factor 21 (FGF21) and its role in metabolic regulation

His studies have provided groundbreaking insights into FGF21’s ability to regulate:
✅ Blood glucose levels
✅ Blood pressure stability
✅ Anti-atherosclerosis mechanisms
✅ Anti-Metabolic Dysfunction-Associated Steatohepatitis (MASH) therapies

Additionally, his work focuses on discovering new therapeutic targets for:
⚕️ Anti-myocardial infarction drugs
⚕️ Anti-heart failure treatments
⚕️ Anti-vascular calcification solutions

🌍IMPACT AND INFLUENCE:

Prof. Lin’s research has had a profound impact on global medical science, particularly in the fields of:
🔹 Metabolic disease management
🔹 Cardiovascular treatment innovations
🔹 Therapeutic drug development

His studies have influenced clinical practices, contributing to better patient outcomes in cardiovascular and metabolic health. His pioneering work in hormonal regulation and metabolic stability has inspired numerous scientists and researchers worldwide.

📄ACADEMIC CITES AND RECOGNITION:

Prof. Lin’s research is widely recognized in high-impact medical journals, with numerous citations supporting his theories. His work on FGF21 metabolic regulation is frequently referenced in the fields of endocrinology, cardiology, and metabolic research. He has been a keynote speaker at international medical conferences, sharing his insights with the global scientific community.

🚀LEGACY AND FUTURE CONTRIBUTIONS:

With an unwavering commitment to scientific innovation, Prof. Lin continues to shape the future of medical research. His ongoing projects aim to:
🔬 Develop novel cardiometabolic therapies
🔬 Enhance cross-organ communication research
🔬 Introduce cutting-edge treatments for heart disease and metabolic disorders

His legacy will be defined by his transformative contributions to medicine, paving the way for future breakthroughs in cardiovascular and metabolic health.

💡CONCLUSION:

Prof. Dr. Zhuofeng Lin is a pioneering leader in cardiometabolic research, making groundbreaking contributions to understanding metabolic regulation and cardiovascular health. His work on FGF21 has revolutionized approaches to blood glucose stability, blood pressure control, and anti-atherosclerosis treatments . With a vision for therapeutic innovation, he continues to explore new drug targets for heart failure, myocardial infarction, and vascular calcification . His impact on medical science is profound, shaping the future of metabolic and cardiovascular treatments. His dedication ensures lasting advancements in healthcare and patient well-being.

TOP NOTABLE PUBLICATIONS

Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice

Authors: Z Lin, H Tian, KSL Lam, S Lin, RCL Hoo, M Konishi, N Itoh, Y Wang, …
Journal: Cell Metabolism
Year: 2013

Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice

Authors: Z Lin, X Pan, F Wu, D Ye, Y Zhang, Y Wang, L Jin, Q Lian, Y Huang, …
Journal: Circulation
Year: 2015

Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile

Authors: Z Lin, Z Wu, X Yin, Y Liu, X Yan, S Lin, J Xiao, X Wang, W Feng, X Li
Journal: PLoS One
Year: 2010

Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues

Authors: L Geng, B Liao, L Jin, Z Huang, CR Triggle, H Ding, J Zhang, Y Huang, …
Journal: Cell Reports
Year: 2019

Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2

Authors: D Ye, K Yang, S Zang, Z Lin, HT Chau, Y Wang, J Zhang, J Shi, A Xu, …
Journal: Journal of Hepatology
Year: 2016

Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese

Authors: Z Lin, Z Zhou, Y Liu, Q Gong, X Yan, J Xiao, X Wang, S Lin, W Feng, X Li
Journal: PLoS One
Year: 2011

FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1–7) axis in mice

Authors: X Pan, Y Shao, F Wu, Y Wang, R Xiong, J Zheng, H Tian, B Wang, …
Journal: Cell Metabolism
Year: 2018

Adiponectin protects against acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice

Authors: Z Lin, F Wu, S Lin, X Pan, L Jin, T Lu, L Shi, Y Wang, A Xu, X Li
Journal: Journal of Hepatology
Year: 2014

Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling‐dependent manner

Authors: Y Pan, B Wang, J Zheng, R Xiong, Z Fan, Y Ye, S Zhang, Q Li, F Gong, …
Journal: Journal of Cellular and Molecular Medicine
Year: 2019

Dynamic change of serum FGF21 levels in response to glucose challenge in human

Authors: Z Lin, Q Gong, C Wu, J Yu, T Lu, X Pan, S Lin, X Li
Journal: The Journal of Clinical Endocrinology & Metabolism
Year: 2012

Lingyan Chen | Cardiovascular Diseases | Best Researcher Award

Posted on by Cardiology and Cardiovascular Medicine

Dr. Lingyan Chen | Cardiovascular Diseases | Best Researcher Award